Mar 12, 2015

CardioCell adds Stony Brook University to sites conducting phase IIa trial

CardioCell, a Stemedica Cell Technologies subsidiary that designs allogeneic stem-cell therapies for cardiovascular indications, has expanded patient recruitment to Stony Brook University’s Heart Institute for its phase IIa clinical trial for chronic heart failure (HF). READ FULL ARTICLE